Literature DB >> 16155061

In vivo activity of mutacin B-Ny266.

Marilaine Mota-Meira1, Helene Morency, Marc C Lavoie.   

Abstract

OBJECTIVES: The objective of this study was to assess the in vivo activity of mutacin B-Ny266 (a bacteriocin produced by Streptococcus mutans) in order to eventually use it as an antibiotic.
METHODS: Intraperitoneal infection was induced with a methicillin-susceptible Staphylococcus aureus strain in mice. Some of the mice were simultaneously injected intraperitoneally with mutacin B-Ny266, some with the vehicle only and some with vancomycin.
RESULTS: While there was 70 and 100% mortality in the control groups of mice, no mortality was observed in the mice injected with vancomycin or mutacin B-Ny266.
CONCLUSIONS: The results presented here show, for the first time, the in vivo efficacy of a mutacin (B-Ny266) against an experimental intraperitoneal infection by S. aureus in a mouse model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16155061     DOI: 10.1093/jac/dki295

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  34 in total

Review 1.  Bacteriocin production: a probiotic trait?

Authors:  Alleson Dobson; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Appl Environ Microbiol       Date:  2011-10-28       Impact factor: 4.792

Review 2.  New horizons for host defense peptides and lantibiotics.

Authors:  Michael John Dawson; Richard W Scott
Journal:  Curr Opin Pharmacol       Date:  2012-07-07       Impact factor: 5.547

3.  Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins.

Authors:  Máire Begley; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Appl Environ Microbiol       Date:  2009-06-26       Impact factor: 4.792

Review 4.  Bacteriocins - a viable alternative to antibiotics?

Authors:  Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Nat Rev Microbiol       Date:  2012-12-24       Impact factor: 60.633

Review 5.  Anti-infective properties of bacteriocins: an update.

Authors:  Riadh Hammami; Benoit Fernandez; Christophe Lacroix; Ismail Fliss
Journal:  Cell Mol Life Sci       Date:  2012-10-30       Impact factor: 9.261

Review 6.  Biochemical Features of Beneficial Microbes: Foundations for Therapeutic Microbiology.

Authors:  Melinda A Engevik; James Versalovic
Journal:  Microbiol Spectr       Date:  2017-10

7.  Comparison of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and Vancomycin Against Gram-Positive Bacteria.

Authors:  Catalin Iancu; Aoife Grainger; Des Field; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Probiotics Antimicrob Proteins       Date:  2012-06       Impact factor: 4.609

8.  Efficacious Analogs of the Lantibiotic Mutacin 1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection.

Authors:  Mengxin Geng; Akshaya Ravichandran; Jerome Escano; Leif Smith
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 9.  The dual role of bacteriocins as anti- and probiotics.

Authors:  O Gillor; A Etzion; M A Riley
Journal:  Appl Microbiol Biotechnol       Date:  2008-10-14       Impact factor: 4.813

10.  Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118.

Authors:  Sinéad C Corr; Yin Li; Christian U Riedel; Paul W O'Toole; Colin Hill; Cormac G M Gahan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.